| Literature DB >> 33727605 |
Martin Weber1, Sang-Won Min2, Oded Foreman3, Abdoulaye Sene4, Baris Bingol5, Tom Truong4, Jeffrey Hung3, Stephanie Dale6, Mike Reichelt3, Savita Ubhayakar6, Carol Cain-Hom7, Miriam Baca3, Zhiyu Jiang2, Qingling Li8, Robert Brendza2, Han Lin2, Chung Kung7, William F Forrest9, Cristine Quiason-Huynh6, Wendy Sandoval8, Buyun Chen6, Yuzhong Deng6, Amy Easton2.
Abstract
Mutations in the GBA1 gene encoding glucocerebrosidase (GCase) are linked to Gaucher (GD) and Parkinson's Disease (PD). Since some GD and PD patients develop ocular phenotypes, we determined whether ocular phenotypes might result from impaired GCase activity and the corresponding accumulation of glucosylceramide (GluCer) and glucosylsphingosine (GluSph) in the Gba1D409V/D409V knock-in (Gba KI/KI; "KI") mouse. Gba KI mice developed age-dependent pupil dilation deficits to an anti-muscarinic agent; histologically, the iris covered the anterior part of the lens with adhesions between the iris and the anterior surface of the lens (posterior synechia). This may prevent pupil dilation in general, beyond an un-responsiveness of the iris to anti-muscarinics. Gba KI mice displayed atrophy and pigment dispersion of the iris, and occlusion of the iridocorneal angle by pigment-laden cells, reminiscent of secondary open angle glaucoma. Gba KI mice showed progressive thinning of the retina consistent with retinal degeneration. GluSph levels were increased in the anterior and posterior segments of the eye, suggesting that accumulation of lipids in the eye may contribute to degeneration in this compartment. We conclude that the Gba KI model provides robust and reproducible eye phenotypes which may be used to test for efficacy and establish biomarkers for GBA1-related therapies.Entities:
Year: 2021 PMID: 33727605 PMCID: PMC7971029 DOI: 10.1038/s41598-021-85528-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379